Centro Médico Teknon
Centro Médico Teknon
Hiszpania, Barcelona
Joan Carles Galceran
39 lat doświadczenia • 1200+ procedury na koncie
Akredytacje :
Kidney cancer treatment cost in Spain typically starts with diagnostics like a PET-CT scan, which costs $1,300 to $1,800. Surgical options, such as laparoscopic nephrectomy, range from $12,000 to $18,000, while advanced robotic-assisted procedures run from $20,000 to $30,000. Total expenses depend on the disease stage and technology used. Patients often save 40-70% compared to the United States. Top treatment hubs include Barcelona, Madrid, and Pamplona.
Typical Kidney Cancer Treatment Costs in Spain
Bookimed Expert Insight: Surgical innovation provides the best value for complex cases. Dr. Antonio Alcaraz at Hospital Quiron Barcelona is a global pioneer in robotic nephrectomy. For pediatric cases, SJD Barcelona Children’s Hospital offers specialized care with high cure rates. Patients seeking clinical trials may benefit from Quironsalud Madrid’s programs. JCI-accredited centers like Centro Médico Teknon or Clinica Universidad de Navarra ensure premium safety standards.
| Turcja | Austria | Hiszpania | |
| Usunięcie nerki | od $10,000 | od $22,000 | od $15,000 |
| Terapia protonowa | od $70,000 | od $80,000 | od $25,825 |
| System da Vinci do chirurgii robotycznej | od $9,500 | od $22,000 | od $17,000 |
| Radioterapia raka odbytnicy | od $7,000 | od $12,000 | od $10,000 |
| Nefrektomia z użyciem robota Da Vinci | od $10,000 | od $16,000 | od $20,000 |
Dr Antonio Alcaraz przeprowadził ponad 500 udanych operacji urologicznych w Centrum Medycznym Teknon, stosując w wielu przypadkach techniki małoinwazyjne.
Dr. Enrique Grande, MD, PhD, MSc, is a medical oncologist with more than 20 years of experience. He is an international expert in genitourinary and neuroendocrine tumors. He directs the Medical Oncology Department and the One Oncology Madrid Cancer Program at QuirónSalud, Spain’s largest private healthcare network. He leads an integrated, multidisciplinary model with access to targeted therapies and clinical trials.
He is a pioneer in precision oncology. He uses molecular profiling and biomarker-based care. He has authored more than 300 peer-reviewed papers. He serves as a principal investigator and sits on steering committees for many international trials. These studies help set standards of care in urothelial bladder and neuroendocrine tumors. He contributes to guidelines and programs at ESMO, ASCO, ENETS, and EAU.
Dr Begoña Mellado González specjalizuje się w nowotworach układu moczowego w Hospital HM Nou Delfos, koncentrując się na innowacyjnych terapiach i badaniach klinicznych.